AbbVie (ABBV) just caught a fresh tailwind after HSBC bumped the stock to a Buy, a move that comes on top of strong quarterly ...

AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

In an increasingly uncertain market, where concentration risk looms large, savvy investors are seeking refuge in quality blue-chip stocks. With about 50% of the market's earnings stemming from the top ...

“We sit in the low 60s in terms of Botox share, and that's a clear leadership position by a large margin in the U.S.,” AbbVie ...

Discover why AbbVie (ABBV) is rated Strong Buy, with robust 2025 growth, diversified revenues, and attractive valuation.

Biogen (BIIB) stock slips as HSBC downgrades to a Sell equivalent rating as part of an analysis that included an upgrade on ...

AbbVie (NYSE: ABBV) has the highest share price of any stock on this list, at more than $200 each. But don't let the price ...

Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful ...

AbbVie’s latest narrative update leaves its fair value estimate steady at roughly $243.55 per share, even as small tweaks to ...

Dividend investing rewards patience. The best dividend stocks don’t just pay consistently—they raise payouts year after year, ...